- Home
- CM vs SNY Comparison
CM vs SNY Comparison
Compare CM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CM | SNY |
|---|---|---|
| Founded | 1867 | 1994 |
| Country | Canada | France |
| Employees | N/A | 74846 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.5B | 104.5B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CM | SNY |
|---|---|---|
| Price | $117.24 | $43.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $107.50 | $58.00 |
| AVG Volume (30 Days) | 1.5M | ★ 4.2M |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | 2.75% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | $3.49 |
| Revenue Next Year | $4.65 | $6.10 |
| P/E Ratio | $15.80 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.00 | $40.89 |
| 52 Week High | $118.08 | $52.68 |
Technical Indicators
Market Signals| Indicator | CM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 54.42 |
| Support Level | $109.44 | $43.32 |
| Resistance Level | N/A | $45.18 |
| Average True Range (ATR) | 2.04 | 0.76 |
| MACD | 0.19 | 0.22 |
| Stochastic Oscillator | 79.61 | 93.18 |
Price Performance
Historical ComparisonAbout CM Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce is Canada's fifth-largest bank with over CAD 1.1 trillion in assets at the end of fiscal 2025. It operates four business segments: Canadian retail and business banking, Canadian commercial banking and wealth management, US commercial banking and wealth management, and capital markets. It serves approximately 14 million personal banking and business customers, primarily in Canada and the US.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.